Richard Moulson
Net worth: 427 $ as of 30/04/2024
Profile
Richard Moulson served as Chief Financial Officer & Director at Evgen Pharma Plc, Chief Financial Officer at ReNeuron Group Plc, Chief Financial Officer & Secretary at Regenerative Medicine Assets Ltd., and Chief Financial Officer at Sterecycle (Rotherham) Ltd.
He also served as Chief Financial Officer at Intercytex Ltd.
from 2002 to 2006.
Moulson received his undergraduate degree from The University of Exeter.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
THERACRYF PLC
0.01% | 31/03/2023 | 45,454 ( 0.01% ) | 427 $ | 30/04/2024 |
Former positions of Richard Moulson
Companies | Position | End |
---|---|---|
Sterecycle (Rotherham) Ltd.
Sterecycle (Rotherham) Ltd. Environmental ServicesIndustrial Services Sterecycle is a waste management business focused on recycling and green energy. It has its own patented technologies that are capable of recycling and recovering the typical household waste stream. Since June 2008 it has been operating a full scale plant in Yorkshire. This is the World's 1st full scale commercial autoclave plant to treat residual household waste. The plant is processing 'black-bag' waste from 3 local authorities under a contract for up to 10 years: Rotherham Metropolitan Borough Council, Barnsley Metropolitan Borough Council and Doncaster Metropolitan Borough Council. Whilst autoclaving has been used for a number of years for sterilizing small batches of medical waste, it has pioneered its use at industrial scale and for recycling municipal solid waste. In addition, the facility uses its own unique autoclaving system which is highly energy efficient and integrated with a green energy plant is self-sustaining with a beneficial carbon footprint. Its technology is protected by a series of granted patents and patent applications. Its business model is to build, own and operate waste recycling plants, processing residual waste as a substitute for landfill. It is a well funded business, backed by blue chip investors including Goldman Sachs, Fidelity International and Impax Asset Management. | Director of Finance/CFO | 06/05/2014 |
Regenerative Medicine Assets Ltd.
Regenerative Medicine Assets Ltd. Pharmaceuticals: MajorHealth Technology Regenerative Medicine Assets Ltd. engaged in the healthcare business. The company was founded by Paul Kemp in 2000 and was headquartered in Bristol, the United Kingdom. | Director of Finance/CFO | 16/09/2008 |
Intercytex Ltd.
Intercytex Ltd. Pharmaceuticals: MajorHealth Technology The company is developing cell-based treatments for skin and hair regeneration. Its TrichoCyte product candidate is injected just beneath the scalp to encourage new hair follicles to form. Another product candidate, ProtoDerm, could treat diabetic ulcers and other chronic dermal wounds. | Director of Finance/CFO | 03/02/2006 |
THERACRYF PLC | Director of Finance/CFO | - |
RENEURON GROUP PLC | Director of Finance/CFO | 23/04/2014 |
Training of Richard Moulson
The University of Exeter | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
RENEURON GROUP PLC | Health Technology |
THERACRYF PLC | Health Services |
Private companies | 3 |
---|---|
Intercytex Ltd.
Intercytex Ltd. Pharmaceuticals: MajorHealth Technology The company is developing cell-based treatments for skin and hair regeneration. Its TrichoCyte product candidate is injected just beneath the scalp to encourage new hair follicles to form. Another product candidate, ProtoDerm, could treat diabetic ulcers and other chronic dermal wounds. | Health Technology |
Regenerative Medicine Assets Ltd.
Regenerative Medicine Assets Ltd. Pharmaceuticals: MajorHealth Technology Regenerative Medicine Assets Ltd. engaged in the healthcare business. The company was founded by Paul Kemp in 2000 and was headquartered in Bristol, the United Kingdom. | Health Technology |
Sterecycle (Rotherham) Ltd.
Sterecycle (Rotherham) Ltd. Environmental ServicesIndustrial Services Sterecycle is a waste management business focused on recycling and green energy. It has its own patented technologies that are capable of recycling and recovering the typical household waste stream. Since June 2008 it has been operating a full scale plant in Yorkshire. This is the World's 1st full scale commercial autoclave plant to treat residual household waste. The plant is processing 'black-bag' waste from 3 local authorities under a contract for up to 10 years: Rotherham Metropolitan Borough Council, Barnsley Metropolitan Borough Council and Doncaster Metropolitan Borough Council. Whilst autoclaving has been used for a number of years for sterilizing small batches of medical waste, it has pioneered its use at industrial scale and for recycling municipal solid waste. In addition, the facility uses its own unique autoclaving system which is highly energy efficient and integrated with a green energy plant is self-sustaining with a beneficial carbon footprint. Its technology is protected by a series of granted patents and patent applications. Its business model is to build, own and operate waste recycling plants, processing residual waste as a substitute for landfill. It is a well funded business, backed by blue chip investors including Goldman Sachs, Fidelity International and Impax Asset Management. | Industrial Services |
- Stock Market
- Insiders
- Richard Moulson